<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852696</url>
  </required_header>
  <id_info>
    <org_study_id>8867</org_study_id>
    <nct_id>NCT00852696</nct_id>
  </id_info>
  <brief_title>Over Active Bladder Patients Having Sling Surgery</brief_title>
  <official_title>A Double Blind, Randomized Placebo Controlled Trial of the Perioperative Use of Solifenacin in the Management of Postoperative Overactive Bladder Symptoms in Patients With Mixed Incontinence Undergoing Suburethral Sling Procedures.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cleveland Clinic Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with anti-muscarinic medications
      following sub-urethral sling procedures improves overall subjective and objective outcomes in
      women with mixed incontinence with primary stress symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with mixed incontinence with primary stress symptoms undergoing Sub-Urethral Sling
      Procedures will be randomized to peri-operative placebo or solifenacin. Subjects in the
      placebo group will take orally once daily for 9 weeks. Subjects in the Solifenacin group will
      take orally once daily for 9 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of solifenacin in the prevention of postoperative OAB symptoms (urinary frequency,urgency, urge incontinence, nocturia) in women undergoing sub-urethral sling placement for mixed urinary incontinence with primary stress symptoms.</measure>
    <time_frame>11 weeks</time_frame>
    <description>Reduction in overactive bladder symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess safety of Solifenacin in women having sub-urethral sling procedures, the perioperative period, on quality of life measures on length of hospitalization on the time to resumption of normal voiding in time to removal of suprapubic catheter.</measure>
    <time_frame>11 weeks</time_frame>
    <description>reduction in urinary incontinence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Orally 9 weeks once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solifenacin Orally 9 weeks once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.</description>
    <arm_group_label>Solifenacin Group</arm_group_label>
    <other_name>Tolterodine Tartrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take orally once daily for 9 weeks.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18

          -  Patient is appropriate for sub-urethral sling procedure

          -  Mixed urinary incontinence

          -  No antimuscarinic therapy for previous 30 days

        Exclusion Criteria:

          -  Uncontrolled narrow angle glaucoma

          -  Acute cystitis

          -  Unevaluated hematuria

          -  Currently using anti-muscarinic therapy

          -  Unable to complete pre-operative urodynamics

          -  Contraindication to anti-cholinergic therapy

          -  Unable or unwilling to complete diaries or quality of life questionaire

          -  Significant (exteriorized) Pelvic Organ Prolapse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G W Davila, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleeland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2009</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>Incontinence</keyword>
  <keyword>Solifenacin</keyword>
  <keyword>Women</keyword>
  <keyword>Postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

